Characteristics of the study population at baseline
| Mean±SD/median (IQR)/n (%) | |
| n | 45 |
| Sex | |
| Male | 25 (55.6) |
| Female | 20 (44.4) |
| Age (years) | 68 (9) |
| Weight (kg) | 96.1±15.2 |
| BMI (kg/m2) | 32.0±4.2 |
| Overweight | 15 (33.3) |
| Obese | 30 (66.7) |
| Years between diagnosis and start intervention* | 11.7±6.6 |
| Use of medication† | |
| Blood glucose lowering | |
| Metformin only | 16 (35.6) |
| Other oral medication (with or without metformin) | 14 (31.1) |
| Insulin (with or without other oral medication) | 15 (33.3) |
| For blood pressure/kidney function† | |
| RAAS-blockage | 27 (60.0) |
| Angiotensin-II blockers | 10 (22.2) |
| ACE-inhibitors | 17 (37.8) |
| Calcium antagonists | 6 (13.3) |
| Bètablockers | 14 (31.1) |
| Diuretics (thiazides or potassium sparing) | 14 (31.1) |
| None | 10 (22.2) |
| No data | 2 (4.4) |
| No or stable use (T0–T6) | 29 (64.4) |
| Changed use (T0–T6) | 11 (24.4) |
| No/insufficient data (T0–T6) | 5 (11.1) |
*Missing data of three participants.
†Participants could be using more than one type or combination drugs. Sum adds up to more than 100%.
BMI, body mass index; IQR, interquartile range; SD, standard deviation.